Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

EHA Pediatric Hemato-Oncology Course 2024

Join us in Sorrento to develop your problem-solving skills and exchange ideas in a friendly and supportive environment. DatesApril 10–13, 2024. LocationGrand Hotel Riviera, Sorrento, Italy.

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

EHA response to the EU’s Pharma Revision

Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.

Travel Grants

Travel grant application is now open Apply here

Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.

Moldova to be allowed to participate in EU4Health projects

The European Commission and the Government of the Republic of Moldova have signed an agreement to associate Moldova with the EU4Health program.

COVID-19 Hematology Hub

European registry on inherited platelet disorders project

An SWG Grant-supported project initiated by EHA's SWG on Thrombocytopenia and Platelet Function Disorders.

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.